Pembrolizumab + axitinib (RCC, 1L all-risk)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PEMBROLIZUMAB DRUG-AXITINIB |
|---|
| ID | REG-PEMBRO-AXI-RCC |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Notes
KEYNOTE-426 workhorse 1L clear-cell mRCC.
Used By
Indication
IND-RCC-METASTATIC-1L-PEMBRO-AXI- IND-RCC-METASTATIC-1L-PEMBRO-AXI